ImmunisBio's Regulatory T Cell Culture Medium Shows Skin Wound Healing Effects, Published in International Journal

[Asia Economy Reporter Hyungsoo Park] Immunis Bio announced on the 13th that a paper proving the wound healing effect of regulatory T (Treg) cell culture supernatant on skin cells was published in the international journal (Dovepress_Clinical, Cosmetic and Investigational Dermatology).

Dr. Jung-hwa Kang, the author of the paper, explained, "Using the company's Treg cell proliferation technology, we were able to obtain Treg cells increased by 60 times compared to the control group," and added, "We obtained satisfactory results confirming the increase of various cytokines such as IL-10 expressed in Treg cells."

She continued, "We confirmed that cytokines included in the Treg cell culture supernatant reduce the expression of matrix metalloproteinases (MMPs), which are protein-degrading enzymes, and E-cadherin, an adhesion protein, and rapidly enhance cell migration ability."

CEO Seong-hwan Hwang said, "We announced meaningful results confirming the excellent selective culture of Treg cells and wound healing results using Treg cell culture supernatant," and added, "We hope that through further research, the results will be applied to autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and Sj?gren's syndrome, which are caused by abnormal immune regulation functions of Treg cells."

Immunis Bio is developing NK and Treg-related cell therapies for cancer and autoimmune disease treatment. The company has launched high-functional cosmeceutical products such as whitening, anti-inflammatory, and skin regeneration. It is expanding its business area by developing automated devices for cell therapy production. In July 2021, it is preparing for a technology-specialized listing on the KOSDAQ market with Shinhan Investment Corp. as the lead manager.

This content was produced with the assistance of AI translation services.